100–250 mg/day of extract standardized to boswellic acids (AKBA).
Pain and stiffness ↓ — outperformed placebo, ibuprofen and glucosamine
View the study (meta-analysis) →⏱ 3 min read
Boswellia serrata, also called Indian frankincense or salai guggal, is the resin of the tree from which the aromatic incense traditionally used in religious ceremonies around the world is extracted; Ayurvedic medicine has used it for millennia as an anti-inflammatory for joint pain and respiratory disorders, and the last twenty years of pharmacological research have confirmed a real clinical profile based on its unique ability to inhibit 5-lipoxygenase, an inflammatory enzyme distinct from the cyclooxygenase targeted by classic pharmacological anti-inflammatories.
The main active compounds are boswellic acids, especially AKBA (3-acetyl-11-keto-β-boswellic acid), which is the most potent of the six boswellic acids identified; extracts standardized to 30-65 percent boswellic acids and 10-30 percent AKBA are the ones that have shown clinical results in published trials, whereas the raw, unstandardized resin has far more variable and unpredictable efficacy.
The strongest indication is knee and hip osteoarthritis: several meta-analyses of randomized trials have shown reductions in pain and improvements in joint function (WOMAC index, visual analog scales) with doses of 100-250 milligrams daily of AKBA-standardized extract (or equivalents) over 4-12 weeks; the effect is comparable to that of some nonsteroidal anti-inflammatory drugs (NSAIDs) without the gastrointestinal and cardiovascular risks of their prolonged use.
The mechanism combines selective inhibition of 5-lipoxygenase (which reduces the synthesis of leukotrienes, inflammatory mediators complementary to prostaglandins), effects on the transcription factor NF-kB, and possible modulation of joint cartilage degradation; this profile, distinct from that of classic NSAIDs, allows it to be combined with other anti-inflammatory strategies without mechanistic overlap, offering a much better-tolerated option for chronic treatment.
In mild to moderate bronchial asthma, several trials have shown significant improvements in spirometric parameters, in the frequency of attacks, and in the use of rescue bronchodilators with doses of 300-400 milligrams three times a day for 6-8 weeks; the effect is attributed to the inhibition of leukotrienes, the same mediators blocked by pharmacological antileukotrienes such as montelukast.
In inflammatory bowel disease (ulcerative colitis, Crohn's disease) the data are promising: several trials have shown efficacy comparable to sulfasalazine in mild to moderate ulcerative colitis, an indication where pharmacological options with a good safety profile are limited and Boswellia offers a reasonable alternative as an adjunct.
In post-radiotherapy cerebral edema, several small trials have shown reductions in edema with high doses (1,200-1,800 mg/day), an indication that is being incorporated into some oncology protocols as an adjunct to reduce dependence on corticosteroids; in neuropathic pain and some chronic headaches there are interesting but not yet consolidated preliminary data.
The doses studied range from 100 to 1,800 milligrams daily depending on the indication: 100-300 mg/day for osteoarthritis with extracts high in AKBA (5-Loxin®, ApresFlex®, Aflapin®), 900-1,200 mg/day for asthma or IBD divided into three doses; branded products with clear AKBA standardization are the best supported by direct clinical evidence, whereas generic extracts can have highly variable activity.
Generally well tolerated; the most common adverse effects are mild digestive discomfort (nausea, diarrhea, heartburn); people taking anticoagulants should be cautious because of a theoretical antiplatelet effect, those taking immunosuppressants should consult first (Boswellia has complex immunomodulatory effects that are not completely characterized), and it is best avoided in pregnancy and breastfeeding because of limited data on reproductive safety.
Information, not medical advice. Scientific evidence reflects the quality of the studies.